Health ProductsDear Healthcare Professional Letter

Thelin (sitaxsentan sodium) - Worldwide Product Withdrawal - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on THELIN

December 15, 2010

Subject: Pfizer Initiates Product Withdrawal of THELIN® (sitaxsentan sodium) Worldwide

Dear Health Care Professional,

Pfizer Canada, in collaboration with Health Canada, is voluntarily withdrawing THELIN® (sitaxsentan sodium) tablets from the Canadian market due to concerns about hepatotoxicity.

  • Prescribers should not issue prescriptions to new patients for THELIN®.
  • Existing THELIN® patients should be transitioned safely to appropriate alternative therapy as soon as possible. THELIN® will remain available to these patients during this transition period.

Pfizer has completed an extensive assessment of the hepatic safety of THELIN®. Based on a review of available information, including new information on two fatalities associated with hepatic injury (a 2009 post-marketing case in the UK and in a 2010 clinical trial case in a US registration program at a study site in India), Pfizer concluded:

  • Hepatotoxicity is a known risk of THELIN® and all endoTHELIN receptor antagonists (ETRAs).
  • A newly identified idiosyncratic pattern of liver injury cannot be excluded at this time as a potential risk of THELIN® use.
  • This idiosyncratic hepatotoxicity does not appear to be associated with identifiable risk factors, does not appear likely to be detected by routine monitoring and, at least in some cases, does not appear to resolve with the discontinuation of THELIN®.
  • Based on the information available at this time and given the availability of alternative treatments, Pfizer has concluded that the overall benefit of THELIN® no longer outweighs the risk in the general population of Pulmonary Arterial Hypertension (PAH) patients.

Given the above conclusions, Pfizer has decided to voluntarily withdraw its marketing license in all countries where it has an approved marketing authorization. Additionally, Pfizer has decided to discontinue all clinical development of sitaxsentan, including the U.S. and Japan Phase 3 registration trials.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving THELIN® should be reported to Pfizer Canada or Health Canada at the following addresses:

Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Telephone: 1-800-463-6001

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:

  • Report online at MedEffectTM Canada Web site
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

For medical or pharmaceutical requests please contact Pfizer Canada Inc's Medical Information Department at 1-800-463-6001.

Sincerely,

original signed by

Bernard Prigent, MD, MBA
Vice-President and Medical Director
Pfizer Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime